Indivior : Drug addiction treatment firm Indivior upgrades outlook and shares take off
June 30, 2021 at 03:41 pm IST
Share
FTSE-listed drug maker Indivior saw its shares surge more than 10 per cent this morning after it raised its annual revenue and profit forecast, encouraged by strong sales of its opioid addiction treatments in the first half of the year as patients resumed routine visits to clinics and hospitals.
The US-based pharma now expects full-year net revenue between $705m and $740m, to account for growth in its injectable opioid addiction treatment, Sublocade, and steady sales of its top-selling medicine, Suboxone.
Shares are currently trading up nine per cent t 159p per share.
In February, Indivior forecast sales of up to $625m on the upside that Covid-19 restrictions, which kept patients away from hospitals and limited access to medicines, would be lifted in the second half of the year.
Opioid addiction has been a crisis in the US, Indivior’s biggest market. The USCenters for Disease Control and Prevention has said nearly 500,000 people died from opioid overdoses in the US from 1999 to 2019.
The company also expects Sublocade sales to be in a range of $210m to $230m, an upgrade from $185m to $210m estimated earlier, after it received a large order from an unnamed customer in the criminal justice system.
Indivior, spun off from Reckitt in 2014, has been focusing on growing newer treatments including Sublocade, and Perseris for schizophrenia to boost its fortunes. Earlier this month, it expanded into treatments for cannabis-related disorders.
The drugmaker, which was grappling with drawn-out legal challenges and competition even before the coronavirus outbreak hammered the healthcare sector, will report interim results on July 29
The post Opioid treatment firm Indivior upgrades outlook and shares take off appeared first on CityAM.
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.